Monument Tx Announces US Patent for MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia
MANCHESTER, UNITED KINGDOM, April 30, 2026 /EINPresswire.com/ -- Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry, today announced that the United States Patent and …